CEO Richard Fair's total reported compensation of approximately $11.9 million for fiscal year 2025 is heavily dominated by a single large equity award of $11.88 million granted upon his hire in December 2025 — this is essentially a new-hire grant covering his initial multi-year tenure, not a standard annual grant, which is typical and appropriate for a CEO joining mid-year. His actual cash salary earned in 2025 was only $38,077 (reflecting less than one month of service at his $660,000 annual rate), meaning virtually all of his reported pay is in the form of equity aligned with long-term stock performance. The company's stock has significantly outperformed the XBI — SPDR S&P Biotech ETF over both the 1-year period (+80.2 percentage points above XBI) and the 3-year period (+58.8 percentage points above XBI), demonstrating strong alignment between shareholder outcomes and executive incentives; the company also has a meaningful clawback policy adopted in August 2023 in compliance with Nasdaq and SEC rules.

Deloitte has served as Enliven's auditor since 2019 (approximately 7 years), well below the 25-year tenure threshold that would raise independence concerns; all fees paid were audit fees with zero non-audit, tax, or other fees, meaning the non-audit fee ratio is 0% — far below the 50% threshold that would trigger a negative vote; Deloitte is a Big 4 firm appropriate for a $2.7B market cap company.